ATXS Projected Dividend Yield
Astria Therapeutics Inc ( NASDAQ : ATXS )Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. Co.'s lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). Co. owns two patent families directed to STAR-0215. 21 YEAR PERFORMANCE RESULTS |
ATXS Dividend History Detail ATXS Dividend News ATXS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |